An FDA advisory panel voted this week to add six peptides to the drug compounding list, including compounds like kisspeptin-10 and TB-500. The panel turned down emideltide. HIMS stock rose as shares jumped overnight after the committee backed four peptides. Bachem's stock remained stable after the vote. A recent study indicated peptides may assist with combating antibiotic-resistant bacteria. Meanwhile, Kennedy called for broader availability to controversial peptides, calling for reduced restrictions. The vote reflects a broader shift in how regulators view compounded peptide therapies, which have drawn increasing interest from consumers seeking alternatives to traditional drugs. Investigators say peptide treatments could change approaches to difficult infections, though concerns about safety persist. The committee's endorsement of six peptides clears a path for more widespread prescribing, even as skeptics warn of short-term evidence. Market watchers note that peptide-focused companies may see greater investor attention following the panel's decision. The rejection of emideltide, meanwhile, signals the FDA's cautious stance on some peptide candidates.